Inoviq Ltd · ASX:IIQ
Inoviq — Investor Day (February 2026)
27 slides from Inoviq's investor day presentation, Feb 18, 2026
Slide 1: INOVIQ overview
INOVIQ overview Next-generation cancer diagnostics and therapeutics 18th February 2026 ASX: IIQ
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) Actual results, performance or achievements could be significantly different from those based on information available to it as at the date of this presentation. This presentation expressed in, or implied by
Slide 3: INOVIQ's mission is to transform patient lives through earlier cancer detection
INOVIQ’s mission is to transform patient lives through earlier cancer detection and more effective treatments, powered by proprietary exosome technologies 3
Slide 4: INOVIQ's exosome technologies enable advanced diagnostics and therapeutics
INOVIQ’s exosome technologies enable advanced diagnostics and therapeutics Exosomes are the body's natural information-carrying nanoparticle — tiny packages released by all cells that transport RNA, proteins and lipids to communicate messages from the parent to recipient cells • Window into disease
Slide 5: INOVIQ is pioneering next-generation diagnostics and therapeutics
INOVIQ is pioneering next-generation diagnostics and therapeutics that transform care cancer Financial snapshot (ASX:IIQ) Market capitalisation A$46.5m Proprietary exosome platform enables high-performance diagnostics and targeted exosome therapeutics Share price (13 Feb 2026) A$0.33 52-week H/L A$0
Slide 6: EXO-OC Ovarian Cancer Screening Test
EXO-OC Ovarian Cancer Screening Test Simple blood test for early detection of OC in asymptomatic average-risk women aged ~45-74 EXO-OC Overview Patented EXO-NET® technology used to isolate exosomes Detected 100% of early-stage I & II ovarian cancers Combines multiple exosomal miRNA + CA125 biomarker
Slide 7: EXO-OC | Development pathway for high-impact diagnostics
EXO-OC | Development pathway for high-impact diagnostics In Progress Biomarker Assay Analytical Clinical Marketing Clinical Utility Adoption Qualification Development Validation Validation Approval •Select markers •Design assay •Characterise test •Validate •Pivotal •Regulatory •Clinical guideline an
Slide 8: CAR-Exosomes are a cell-free therapy to target and kill solid tumours
CAR-Exosomes are a cell-free therapy to target and kill solid tumours Off-the-shelf, cell-free therapy Stable & Multiple Cell-free therapy for treatment of solid tumours with potential easier to therapeutic cost, safety and efficacy advantages over autologous cell therapies manufacture applications
Slide 9: CAR-Exosomes PoC achieved with positive efficacy and safety results
CAR-Exosomes PoC achieved with positive efficacy and safety results Positive in vivo PoC Results for CAR-NK-EVs in Triple-Negative Breast Cancer Key Findings Superior Tumour Inhibition Outstanding Survival CAR-EVs reduced tumour burden by 100% survival of CAR-EV treated mice 61.5% Excellent Safety P
Slide 10: Future Catalysts | Driving growth and value across our pipeline
Future Catalysts| Driving growth and value across our pipeline Jul-25 Dec-25 Jun-26 Dec-26 EXO-NET • EXO-NET sales growth, collaborations & diagnostic partnering (research tools) EXO-OC Commence clinical studies for OC • Strategic partnering for LDT • Analytical and clinical validation (OC screeni
Slide 11: Summary | Positioned for growth
Summary| Positioned for growth Leading exosome company Exosome research tools Clinical-stage EXO-OC with proven technology partnered, on-market and screening test targeting platform and best-in-class generating initial revenue significant unmet need in research tools, diagnostics with potential for
Slide 12: Contacts
Contacts Dr Leearne Hinch BVMS MBA Dr Emma Ball PhD MBA GAICD Chief Executive Officer Chief Commercial Officer e. lhinch@inoviq.com e. eball@inoviq.com INOVIQ Ltd, 23 Normanby Road, Notting Hill, VIC 3168 Australia 12 p. +61 3 9548 7586 | e. info@inoviq.com | w. www.inoviq.com
Slide 13: Appendices
Appendices Y pes» =INOVIQ
Slide 14: Glossary
Glossary AUC area under the curve IVD in vitro diagnostic BC breast cancer KOL key opinion leader CA125 cancer antigen 125 biomarker (used in ovarian cancer monitoring) LDT laboratory developed test CA15-3 cancer antigen 15-3 biomarker (used in breast cancer monitoring) MIA in vitro multivariate ind
Slide 15: Leadership | Corporate, scientific, clinical and commercial expertise
Leadership| Corporate, scientific, clinical and commercial expertise DR LEEARNE HINCH BVMS MBA MARK EDWARDS BAcc CA EMMA BALL PhD MBA GAICD Chief Executive Officer CFO & Company Secretary Chief Commercial Officer Biotechnology CEO with a proven track record in Experienced finance executive with expe
Slide 16: Board | Capital markets, healthcare and biotech experience
Board| Capital markets, healthcare and biotech experience PETER GUNZBURG MAX JOHNSTON PHILIP POWELL Non-Executive Chairman Non-Executive Director Non-Executive Director Experienced public company director, Healthcare industry director and Healthcare industry director and stockbroker and investor wit
Slide 17: EXO-OC | Ovarian cancer screening test
EXO-OC | Ovarian cancer screening test Exosome-based blood test in development for screening Percent of Samples Correctly Identified by EXO-OC Ovarian Cancer in asymptomatic, average-risk women • Patented EXO-NET® technology used to isolate exosomes • Combines multiple exosomal miRNA and CA125 bioma
Slide 18: EXO-OC | Commercialisation strategy
EXO-OC | Commercialisation strategy Dual-path commercialisation strategy to maximise speed, access and value for patients, clinicians & investors Laboratory Developed Test In Vitro Diagnostic (LDT) (IVD) Laboratory partner Large diagnostics company Partner to offer testing service via for global sca
Slide 19: EXO-OC | Clinical and regulatory strategy
EXO-OC | Clinical and regulatory strategy Commercialisation pathways Intended use • Screening test for Ovarian Cancer in asymptomatic, average- LDT PATHWAY IVD PATHWAY risk women aged 45 - 74 Clinical Studies (in-house / CRO) ~2K Cohort, Disease Specificity, High-Risk H2 2025 Retrospective clinical
Slide 20: Ovarian Cancer in 9 Major Markets
Ovarian Cancer in 9 Major Markets Market Incidence Prevalence Eligible Population General Annual (5-year) (45-74yo) 1 Screening Addressable Participation Population 11 2 China 61,060 180,870 282,713,102 51.4% 145,201,449 3 USA 21,179 68,388 60,689,385 75.7% 45,941,864 4 Japan 10,693 33,732 24,907,72
Slide 21: Diagnostic Deals | Liquid biopsy platforms
Diagnostic Deals| Liquid biopsy platforms Upfront Milestones Total Deal Value Acquiror / Licensee Target / Licensor Date Deal Type Stage Technology (US$m) (US$m) (US$m) Various oncology screening, detection, monitoring and 1 2025 Acquisition Commercial N/A N/A $23,000 risk profile tests, $3.2B reven
Slide 22: CAR-Exosomes | Cost-effective process compared to Cell Therapy
CAR-Exosomes| Cost-effective process compared to Cell Therapy Cell Therapy next generation CAR-Exosome Therapy Centralised GMP Manufacturing Facility Reprogram to kill Grow enough cells for a cancer cells treatment dose Immune cell Reprogram exosome Cell bank Grow - unlimited Collect white Infuse CA
Slide 23: CAR-Exosomes | Targeted therapy for Triple-Negative Breast Cancer
CAR-Exosomes| Targeted therapy for Triple-Negative Breast Cancer • Lacks key targets: TNBC does not express ER, PR or HER2, making it unresponsive to hormone or HER2-targeted In Vitro effect of CAR-NK-EVs on cell viability in TNBC cells therapies untreated • Limited treatment options: Chemotherapy (
Slide 24: CAR-Exosomes | Therapeutic development path
CAR-Exosomes| Therapeutic development path EXO-ACE In Vivo CRO / Site First Patient CAR EV Isolation Studies Selection Dose 2023 2024 2025 2026 2028 CAR-T / NK Cell In Vitro Process & Analytical Development, IND ‘Study May Development Studies CDMO selection, IND-enabling studies & Proceed’ and Site
Slide 25: Therapeutic Deals | Exosome & cell therapies
Therapeutic Deals| Exosome & cell therapies Upfront Milestones Total Deal Value Acquirer / Licensee Target / Licensor Date Deal Type Stage Cell Source (US$m) (US$m) (US$m) 1 2026 Acquisition Preclinical $2,400 N/A $2,400 in vivo CAR 2 2025 Acquisition Preclinical $1,500 N/A $1,500 in vivo CAR 3 2025
Slide 26: References | Ovarian Cancer in 9 Major Markets
References| Ovarian Cancer in 9 Major Markets 1. United Nations, Data Portal, Population Division, 2024 data 2. The Lancet, Volume 55, Special Issue 101426, February 2025 3. Up-to-Date Breast, Cervical, and Colorectal Cancer Screening Test Use in the United States, 2021, CDC, https://www.cdc.gov/pcd
Slide 27: References | Diagnostic & therapeutic deals
References| Diagnostic & therapeutic deals Diagnostic deals| Liquid biopsy platforms 1. Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision, 20 November 2025 2. Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and De